Navigation Links
GeoVax to Present at the BIO CEO & Investor Conference 2009
Date:1/28/2009

professionals as well as senior executives from our industry sector," stated Dr. McNally.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already infected with AIDS virus.

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertaintie
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Avicena Group to Present at Noble Financial Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... CA (PRWEB) May 06, 2015 ... today announced NX-Hivac, the only high vacuum AFM system ... needs for failure analysis semiconductor manufacturing. Park NX-Hivac is ... in failure analysis solutions in highly doped semiconductor processing ... required. , The high vacuum scanning spreading resistance ...
(Date:5/6/2015)... , May 6, 2015 Dr Jaspreet ... Massey University, will deliver a speech at the 2015 Asian ... the Shanghai New Expo Center.  ... introduce to attendees the topic: ,Potato Starch: A Potential ... Smart Foods., Co-editor of a 528 page ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
(Date:5/5/2015)... 5, 2015  23andMe, Inc., the leading personal genetics ... Research Study in collaboration with Pfizer Inc. The ... erythematosus, more commonly known as lupus, into the study ... effort is also in collaboration with the Lupus Research ... May. Approximately 1.5 million people in the ...
Breaking Biology Technology:Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Blueprint Medicines Announces Closing of Initial Public Offering 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3
... 31, 2012  bioTheranostics, Inc., a bioMerieux company that ... treatment, has introduced a new product line of ... pathway interrogation called PRECIS Precision Medicine by bioTheranostics(SM). ... partners accurate diagnosis of primary tumor site and ...
... rap music can be harnessed to power a new type ... body. Acoustic waves from music, particularly rap, were found ... ultimately help to treat people stricken with aneurisms or incontinence ... a vibrating cantilever, a thin beam attached at one end ...
... The technique builds on previous research in which microbubbles were ... produce an oil which can be processed to create a ... important alternative to fossil fuels and algae, in particular, has ... now, however, there has been no cost-effective method of harvesting ...
Cached Biology Technology:bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 2bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 3Rap music powers rhythmic action of medical sensor 2Rap music powers rhythmic action of medical sensor 3Microbubbles provide new boost for biofuel production 2
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... CA -- Li Qian, PhD, has won the Louis ... for Young Investigators from the American Heart Association (AHA), ... that a Gladstone Institutes researcher has been the recipient. ... Gladstone -- a leading and independent biomedical-research organization -- ...
... 2011   Life Technologies Corporation (NASDAQ: ... company has introduced its GeneArt® Algae Engineering Kits, ... systems for photosynthetic microalgae Chlamydomonas reinhardtii ... model organisms for the study of photosynthesis, circadian ...
... is available in French . , MONTREAL, November ... a leukemic relapse in young patients is a step closer ... and the University of Montreal. Approximately 20 percent of young ... umbilical cord blood will experience leukemic relapse. The researchers, findings, ...
Cached Biology News:Gladstone scientist receives American Heart Association's Katz prize for cardiovascular research 2GeneArt® Algae Engineering Kits by Life Technologies™ 2GeneArt® Algae Engineering Kits by Life Technologies™ 3New hope for young leukemia patients? 2
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Rabbit polyclonal to ThPok ( Abpromise for ... Synthetic peptide conjugated to KLH derived from within ... (Note: the amino acid sequence is proprietary) ... .) Entrez Gene ID: ...
Biology Products: